Frataxin: Its role in iron metabolism and the pathogenesis of Friedreich's ataxia

International Journal of Biochemistry and Cell Biology

Volumn 33, Issue 1, 2001, Pages 1-10

  Becker, Erika ^a,b   Richardson, Des R ^a  

^a HEART RESEARCH INSTITUTE   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Frataxin; Friedreich's ataxia; Iron metabolism

Indexed keywords

FRATAXIN; IRON CHELATING AGENT;

BRAIN MITOCHONDRION; FRIEDREICH ATAXIA; GENE CONTROL; GENE DELETION; GENE EXPRESSION; IRON METABOLISM; IRON OVERLOAD; IRON TRANSPORT; MEMBRANE PERMEABILITY; PATHOGENESIS; REVIEW;

FRIEDREICH ATAXIA; HUMANS; IRON; IRON-BINDING PROTEINS; MUTATION; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); TRINUCLEOTIDE REPEAT EXPANSION;

ATAXIA;

EID: 0035122450     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1357-2725(00)00067-4     Document Type: Review

References (70)

1. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells
2. Function and regulation of transferrin and ferritin
3. Seminars in Liver Disease
4. Transferrin: Biochemistry, physiology and clinical significance
5. Micropinocytosis of transferrin by developing red cells: An electron-microscopic study utilizing ferritin-conjugated transferrin and ferritin-conjugated antibodies to transferrin
6. Effect of iron saturation on transferrin uptake by reticulocytes. A morphological study
7. Cloning and characterisation of a mammalian proton-coupled metal-ion transporter
8. Microcytic anemia mice have a mutation in Nramp2, a candidate iron transporter gene
9. Tissue-specific regulation of iron metabolism and heme synthesis: Distinct control mechanisms in erythroid cells
10. Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress
11. Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia
12. Friedreich's ataxia: Autosomal recessive disease caused by an intronic GAA triplet repeat expansion
13. Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes
14. Respiratory deficiency due to loss of mitochondrial DNA in yeast lacking the frataxin homologue
15. Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia
16. Mitochondrial intermediate peptidase and the yeast frataxin homolog together maintain mitochondrial iron homeostasis in Saccharomyces cerevisiae
17. The yeast frataxin homologue mediates mitochondrial iron efflux
18. Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia
19. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin
20. Deletion of the yeast homologue of the human gene associated with Friedreich's ataxia ellicits iron accumulation in the mitochondrion
21. Studies of human, mouse and yeast homologues indicate a mitochondrial function for frataxin
22. Friedreich's ataxia protein: Bacterial homologs point to mitochondrial dysfunction
23. The Friedreich's ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis
24. Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia
25. Pathology of the heart in Friedreich's ataxia
26. Cardiac iron deposits in Friedreich's ataxia
27. Erythrocyte protoporphyrin levels in patients with Friedreich's and other ataxias
28. An ABC transporter in the mitochondrial inner membrane is required for normal growth of yeast
29. The ABC transporter Atm1p is required for mitochondrial iron homeostasis
30. The mitochondrial proteins Atm1p and Nfs1p are essential for biogenesis of cytosolic Fe/S proteins
31. CCC1 suppresses mitochondrial damage in the yeast model of Friedrech's ataxia by limiting mitochondrial iron accumulation
32. Iron in the central nervous system of Friedreich ataxia patients
33. Increased iron in the dentate nucleus of patients with Friedreich's ataxia
34. Distribution of iron in reticulocytes after inhibition of heme synthesis with succinylacetone: Examination of the intermediates involved in iron metabolism
35. Localization of Friedrech ataxia phenotype with selective vitamin E deficiency to chromosome 8q by homozygosity mapping
36. Ataxia with vitamin E deficiency: Refinement of genetic localization and analysis of linkage disequilibrium by using new markers in 14 families
37. Ataxia with isolated vitamin E deficiency is caused by mutations in the α-tocopherol transfer protein
38. Vitamin E in humans: Demand and delivery
39. Growth factors and vitamin E modify neuronal glutamate toxicity
40. Vitamin E as an antioxidant/free radical scavenger against amyloid beta-peptide-induced oxidative stress in neocortical synaptosomal membranes and hippocampal neurons in culture: Insights into Alzheimer's disease
41. The cardiomyopathy of Friedrech's ataxia
42. Evidence for mitochondrial iron overload in patients with Friedreich's ataxia
43. The effect of the iron(III) chelator, desferrioxamine, on iron and transferrin uptake by the human malignant melanoma cell
44. The effect of various chelating agents on the mobilization of iron from reticulocytes in the presence and absence of pyridoxal isonicotinoyl hydrazone
45. Mobilisation of iron from reticulocytes. Idntification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent
46. A study of intracellular iron metabolism using pyridoxal isonicotinoyl hydrazone and other synthetic chelating agents
47. Effective iron chelation following oral administration of an isoniazid pyridoxal hydrazone
48. Biliary iron excretion in rats following pyridoxal isonicotinoyl hydrazone
49. Pyridoxal isonicotinoyl hydrazone. Effective iron chelation after oral administration
50. Pyridoxal isonicotinoyl hydrazone: An effective iron-chelator after oral administration
51. Effect of pyridoxal isonicotinoyl hydrazone (PIH) and other hydrazones on iron release from macrophages, reticulocytes and hepatocytes
52. Evaluation of the iron chelation potential of hydrazones of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture
53. Biliary iron excretion in rats following treatment with analogues of pyridoxal isonicotinoyl hydrazone
54. Pyridoxal isonicotinoyl hydrazone and its analogs: Potential orally effective iron-chelating agents for the treatment of iron overload disease
55. Iron chelators of the pyridoxal isonicotinoyl hydrazone class III. Formation constants with calcium(II), magnesium(II) and zinc(II)
56. Iron chelators of the pyridoxal isonicotinoyl hydrazone class Part 2. Formation constants with iron(III) and iron(II)
57. Iron chelators of the pyridoxal isonicotinoyl hydrazone class Part I. Ionization characteristics of the ligands and their relevance to biological properties
58. Development of novel aroylhydrazone ligands for iron chelation therapy: 2-Pyridylcarboxaldehyde isonicotinoyl hydrazone (PCIH) analogues
59. The biologically active iron chelators 2-pyridylcarboxaldehyde isonicotinoyl hydrazone, 2-pyridylcarboxaldehyde benzoyl hydrazone and 2-furfural isonicotinoyl hydrazone
60. Therapeutic potential of iron chelators
61. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major
62. Long-term trial of deferiprone in 51-transfusion-dependent iron overloaded patients
63. Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients
64. A treatable familial neuropathy with isolated vitamin E deficiency, normal absorption, and evidence of increased consumption of vitamin E
65. Towards a prevention of cardiomyopathy by idebenone in Friedreich ataxia
66. Effect of idebenone on cardiomyopathy in Friedreich's ataxia: A preliminary study
67. Assessment of coenzyme Q10 tolerability in Huntington's disease
68. Neuroprotective effects of CoQ10 and creatine